Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of L-serine supplementation in children with a GRIN2B loss-of-function mutation: Rationale and protocol for single patient (n-of-1) multiple cross-over trials.
den Hollander B, Rothuizen-Lindenschot M, Geertjens L, Vaz FM, Brands MM, Le HL, van Eeghen AM, van de Ven PM, Cornel MC, Jacobs BAW, Bruining H, van Karnebeek CD. den Hollander B, et al. Among authors: jacobs baw. Contemp Clin Trials Commun. 2023 Nov 17;36:101233. doi: 10.1016/j.conctc.2023.101233. eCollection 2023 Dec. Contemp Clin Trials Commun. 2023. PMID: 38144875 Free PMC article.
Evidence for effect of l-serine, a novel therapy for GRIN2B-related neurodevelopmental disorder.
den Hollander B, Veenvliet ARJ, Rothuizen-Lindenschot M, van Essen P, Peters G, Santos-Gómez A, Olivella M, Altafaj X, Brands MM, Jacobs BAW, van Karnebeek CD. den Hollander B, et al. Among authors: jacobs baw. Mol Genet Metab. 2023 Mar;138(3):107523. doi: 10.1016/j.ymgme.2023.107523. Epub 2023 Jan 21. Mol Genet Metab. 2023. PMID: 36758276 Free article.
Corrigendum to "Effectiveness of L-serine supplementation in children with a GRIN2B loss-of-function mutation: Rationale and protocol for single patient (n-of-1) multiple cross-over trials" [Contemp. Clin. Trials Commun. 36 (2023)/ DOI: 10.1016/j.conctc.2023.101233].
Hollander BD, Rothuizen-Lindenschot M, Geertjens L, Vaz FM, Brands MM, Le HL, van Eeghen AM, van de Ven PM, Cornel MC, Jacobs BAW, Bruining H, van Karnebeek CD. Hollander BD, et al. Among authors: jacobs baw. Contemp Clin Trials Commun. 2024 Feb 1;38:101264. doi: 10.1016/j.conctc.2024.101264. eCollection 2024 Apr. Contemp Clin Trials Commun. 2024. PMID: 38533474 Free PMC article.
Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.
Jacobs BA, Deenen MJ, Pluim D, van Hasselt JG, Krähenbühl MD, van Geel RM, de Vries N, Rosing H, Meulendijks D, Burylo AM, Cats A, Beijnen JH, Huitema AD, Schellens JH. Jacobs BA, et al. Br J Clin Pharmacol. 2016 Sep;82(3):706-16. doi: 10.1111/bcp.13007. Epub 2016 Jun 3. Br J Clin Pharmacol. 2016. PMID: 27161955 Free PMC article.
Access to medicines for rare diseases: A European regulatory roadmap for academia.
Rosenberg N, van den Berg S, Stolwijk NN, Jacobs BAW, Post HC, Pasmooij AMG, de Visser SJ, Hollak CEM. Rosenberg N, et al. Among authors: jacobs baw. Front Pharmacol. 2023 Feb 28;14:1142351. doi: 10.3389/fphar.2023.1142351. eCollection 2023. Front Pharmacol. 2023. PMID: 36925633 Free PMC article.
35 results